Hematological Toxicity of Combined Lutetium-177 Octreotate Radiopeptide-Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors Followed Long-Term

#932

Introduction: Combination radiopeptide therapy (PRRT) with radiosensitizing chemotherapy of gastroenteropancreatic neuroendocrine tumors (GEP NETs) may improve efficacy, but has the potential to increase myelotoxicity.

Aim(s): In a prospective clinical study of GEP NET patients treated with Lutetium-177 octreotate PRRT in combination with capecitabine and temozolomide, we characterized the incidence and degree of hematological toxicity.

Materials and methods: Well-differentiated progressive metastatic GEP-NETS in 65 patients were treated with four cycles of 7.8 GBq 177Lu-octreotate, 1650 mg/m2 capecitabine (n=28) and 1500 mg/m2 capecitabine with 200 mg/m2 temozolomide (n=37), and monitored for hematological toxicity over a 5-year period.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Kesavan M

Authors: Kesavan M, Claringbold P, Turner J,

Keywords: PRRT, GEP-NET,

To read the full abstract, please log into your ENETS Member account.